Immuneering CORP Form 4 insider transactions

Andrew Gengos, Chief Financial Officer of Immuneering Corp, received 650,000 shares of common stock on July 16, 2026.

Immuneering Corp's President and CEO, Benjamin J. Zeskind, has acquired 2,400 shares of Class A Common Stock.

Director Thomas J. Schall was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Director Diana Hausman was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Director Robert J. Carpenter was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Director Laurie Keating was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Director Peter Feinberg was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Immuneering Corp's Chief People Officer, Leah R. Neufeld, acquired 3,628 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Immuneering Corp. granted 176,000 stock options to Chief Legal Officer Michael Bookman, vesting over four years.

Immuneering Corp's Chief Business Officer, Harold Brakewood, was granted 140,000 stock options with an exercise price of $4.91, vesting over four years.

Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, was granted 344,000 stock options with a strike price of $4.91, vesting over four years.

Immuneering Corp's Chief Medical Officer, Igor Matushansky, was granted 140,000 stock options with a $4.91 exercise price, vesting over four years.

Immuneering Corp's SVP Finance, Mallory Morales, was granted 140,000 stock options with an exercise price of $4.91, vesting over four years.

Immuneering Corp's Chief People Officer, Leah R. Neufeld, was granted 140,000 stock options with an exercise price of $4.91, vesting over four years.

Immuneering Corp's President and CEO, Benjamin J. Zeskind, was granted 688,000 stock options with an exercise price of $4.91, vesting over four years.

Immuneering Corp's Chief Business Officer, Harold Brakewood, acquired 5,250 shares of Class A Common Stock at $4.76 per share on January 16, 2026, through a pre-arranged trading plan.

Immuneering Corp Director Thomas J. Schall acquired 21,645 shares of Class A Common Stock in a pre-planned transaction.

Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, acquired 2,298 shares of Class A Common Stock at a weighted average price of $4.57 per share.

Immuneering Corp's Chief People Officer, Leah R. Neufeld, acquired 2,626 shares of Class A Common Stock at $4.153 per share under a pre-arranged trading plan.

Immuneering Corp. Director Peter Feinberg acquired 20,000 shares of Class A Common Stock at a weighted average price of $4.3452.

Immuneering Corp Director Laurie Keating elected to receive 7,888 stock options with a $6.58 exercise price in lieu of a cash retainer.

Immuneering Corp. Director Peter Feinberg elected to receive 7,888 stock options with a $6.58 exercise price in lieu of cash compensation.

Immuneering Corp. Director Peter Feinberg acquired 7,500 shares of Class A Common Stock at $6.67 per share, increasing his direct beneficial ownership.

Immuneering Corp's Chief Accounting Officer, Mallory Morales, purchased 300 shares of Class A Common Stock.

Immuneering Corp's Chief People Officer, Leah R. Neufeld, will acquire 800 shares of Class A Common Stock on October 1, 2025, under a 10b5-1 plan.

Immuneering Corp's Chief Legal Officer, Michael Bookman, purchased 1,020 shares of Class A Common Stock.

Immuneering Corp. Director Peter Feinberg increased his stake by acquiring 7,500 shares of Class A Common Stock at a weighted average price of $7.0307.

Immuneering Corp Director Peter Feinberg acquired 5,000 shares of Class A Common Stock at $7.18 per share, increasing his beneficial ownership.

Immuneering Corp's Chief People Officer, Leah R. Neufeld, acquired 11,815 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Immuneering Corp's Chief Accounting Officer, Mallory Morales, acquired 14,497 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.